The Food & Drug Administration has formed an agency-wide BPA (Bisphenol A) task force to facilitate cross-agency review of current research and new information on BPA for all FDA regulated products. As a result of this review, the task force will make recommendations to the Commissioner regarding next steps.

As part of the evaluation, the FDA Task Force is reviewing the concerns presented in the National Toxicology Program (NTP) Draft Brief published on April 14, 2008 by the U.S. National Institutes of Health. We also are reviewing the concerns presented in the Canadian draft risk assessment released in April 2008 and are coordinating closely with Health Canada and the Canadian Ministry of the Environment and Minister of Health.
FDA has been reviewing the emerging literature on BPA on a continuous basis. 

For example, FDA has recently completed a review of the available biological fate data and two recently completed rodent multigeneration reproductive studies; these studies did not indicate a safety concern for BPA at current exposure levels.  In addition, FDA is conducting a review of the data on neural and behavioral effects of BPA exposure. 

Based on our ongoing review, we believe there is a large body of evidence that indicates that FDA-regulated products containing BPA currently on the market are safe and that exposure levels to BPA from food contact materials, including for infants and children, are below those that may cause health effects.   However, we will continue to consider new research and information as they become available.

This position is consistent with two risk assessments for BPA conducted by the European Food Safety Authority (EFSA) Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food and the Japanese National Institute of Advanced Industrial Science and Technology.  Each of these documents considered the question of a possible low-dose effect and concluded that no current health risk exists for BPA at the current exposure level.

At this time, FDA is not recommending that anyone discontinue using products that contain BPA while we continue our risk assessment process. However, concerned consumers should know that several alternatives to polycarbonate baby bottles exist, including glass baby bottles.